Administer barbiturates with warning in individuals with hepatic harm and at lessened doses originally; barbiturates really should not be administered to patients showing the premonitory indications of hepatic comapentobarbital decreases levels of panobinostat by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Solid CYP3A4 i